Live
- Punjab Congress chief challenges BJP to nominate state prez Jakhar to contest polls
- Mamata Banerjee continues to fire salvos at Calcutta HC against ruling in school jobs case
- Indian healthcare platform exposed 4.5 lakh sensitive documents, clinical data of patients: Report
- Pratani Ramakrishna Goud’s ‘Dhiksha’ marks grand commencement
- Satyadev shines in raw action avatar with ‘Krishnamma;’ set for a grand release on May 10
- South Korea, Japan could consider simplified entry agreement amid warming ties: Seoul official
- Special Polling Arrangements And Voter Facilities In Outer Manipur Lok Sabha Seat
- Shruti Haasan’s ethnic wear look captivated onlookers
- Crucial schedule of ‘Kubera’ starts in Mumbai
- ‘Rathnam’ review: A worthy addition to Vishal’s filmography
Laurus plant gets 3 observations
Highlights
Laurus Labs Limited, on Thursday said that it has completed the USFDA, Pre-Approval Inspection (PAI) for an API manufactured at its Units 1&3, located at J N Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature.
Hyderabad: Laurus Labs Limited, on Thursday said that it has completed the USFDA, Pre-Approval Inspection (PAI) for an API manufactured at its Units 1&3, located at J N Pharma City, Parawada, Visakhapatnam, Andhra Pradesh, with three observations, which are procedural in nature.
No data integrity issues were observed in the inspection. The inspection was carried out from November 18-21, said the company.
"We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC) and are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business," added the company
Next Story
ADVERTISEMENT
